期刊
DIABETOLOGIA
卷 53, 期 8, 页码 1581-1589出版社
SPRINGER
DOI: 10.1007/s00125-010-1765-1
关键词
Antidepressant medication; CVD risk; Depression symptoms; Look AHEAD trial
资金
- National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992, DK 046204]
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
- National Institute of Nursing Research
- National Center on Minority Health and Health Disparities
- Office of Research on Women's Health
- Centers for Disease Control and Prevention
- Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01-RR-02719]
- Massachusetts General Hospital Mallinckrodt General Clinical Research Center [M01-RR-01066]
- University of Colorado Health Sciences Center General Clinical Research Center [M01 RR00051]
- Clinical Nutrition Research Unit [P30 DK48520]
- University of Tennessee at Memphis General Clinical Research Center [M01RR00211-40]
- University of Pittsburgh General Clinical Research Center [M01 RR000056 44]
- University of Washington/VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs
To determine the associations of baseline depression symptoms and use of antidepressant medicines (ADMs) with baseline cardiovascular disease (CVD) risk factors in Look AHEAD (Action for Health in Diabetes) trial participants. Look AHEAD participants (n = 5,145; age 58.7 +/- 6.8 years; BMI 35.8 +/- 5.8 kg/m(2)) were assessed for CVD risk factors (elevated HbA(1c) or insulin use, elevated BP or antihypertensive use, elevated lipid levels or lipid-lowering medication, current smoking, BMI a parts per thousand yen30 kg/m(2), lower peak exercise capacity assessed as metabolic equivalents [METs], and ankle-brachial index < 0.9 or > 1.3). Participants also completed the Beck Depression Inventory (BDI) and reported their use of ADMs. Of the participants, 14.7% had BDI scores a parts per thousand yen11, consistent with mild-moderate depression, and 16.5% took ADMs; 4.4% had both depression markers (i.e. elevated symptom scores and took ADMs). In logistic regression analyses of CVD risk (elevated risk factor or use of medication to control the risk factor), controlled for demographic factors, continuous BDI scores and ADM use were each independently associated with elevated BP (or medication), current smoking, BMI a parts per thousand yen30 kg/m(2) and lower MET values. ADM use was also associated with elevated serum lipids or use of lipid-lowering medication. Among Look AHEAD participants, depression symptoms or ADM use on entry to the study were each independently associated with a wide range of CVD risk factors. Future research should assess the temporal dynamics of the relationships of depression symptoms and ADM use with CVD risk factors. Clinicaltrials.gov NCT00017953 This study is funded by the National Institutes of Health with additional support from the Centers for Disease Control and Prevention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据